Skip Navigation LinksHome > June 2010 - Volume 16 - Issue 4 > Risedronate-Induced Arthritis
JCR: Journal of Clinical Rheumatology:
doi: 10.1097/RHU.0b013e3181dfbb15
Case Report

Risedronate-Induced Arthritis

Yemisci, Oya Umit MD; Yalbuzdag, Seniz Akcay MD; Karatas, Metin MD

Collapse Box


In most cases bisphosphonates are the first choice therapy for osteoporosis. We present a case of acute arthritis associated with once-weekly risedronate in a 58-year-old woman with osteoporosis. She developed arthritis 48 hours after the second dose of oral risedronate with elevated serum acute-phase reactants. There was no evidence of rheumatoid arthritis or seronegative arthritis. Her symptoms resolved rapidly with rest, however, recurred after the patient was rechallenged with the same drug 1 week later. Although the mechanism of this potential side effect remains speculative, it is thought to be as a result of the proinflammatory properties of aminobisphosphonates. With the increasing use of bisphosphonates in the treatment and prevention of osteoporosis, physicians should be well aware of this possible side effect of these drugs.

© 2010 Lippincott Williams & Wilkins, Inc.

Follow Us!


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.